secwatch.observer — SEC 8-K summary
======================================

Issuer:     Raphael Pharmaceutical Inc. (RAPH)
CIK:        0001415397
Form:       8-K
Filed at:   2026-09-01T16:51:41+00:00
Accession:  0001213900-26-096113
Event type: other_material
Sentiment:  neutral
Materiality: 0.35
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Raphael Pharmaceutical signs 12-month AI transformation deal with AIcreatesAI for $180K
--------------------------------------------------------------------------------

- Agreement effective July 30, 2026; AIcreatesAI serves as managed AI transformation, commercialization, and growth partner for 12 months.
- Annual fee of $180,000 payable in $15,000 monthly installments; unpaid invoices defer until financing, capital, or revenues arrive.
- Company may issue common shares to satisfy deferred payments with AIcreatesAI's written consent, subject to securities laws and OTC Markets rules.
- AIcreatesAI entitled to 2% of net profits from any company-branded digital token platform, separate from the service fee and subject to board approval.
- Services include website/app/CRM development, marketing, research intelligence, partnership development, and investor communications.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1415397/000121390026096113/0001213900-26-096113-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1415397/000121390026096113/ea0304182-8k_raphael.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-096113

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer